Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
recived 1st dose in 2023 and did not go back to receive the second dose of the vaccine series; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 2023). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: recived 1st dose in 2023 and did not go back to receive the second dose of the vaccine series). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK receipt date: 22-MAY-2025 The reporter was the patient who received the Shingrix vaccine in 2023 and did not go back to receive the second dose of the vaccine series. The patient did not wanted to give any information after he was told that a safety report would be filed. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.